Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunovant, Inc. - Common Stock (NQ:IMVT)

43.94 +0.44 (+1.01%)
Streaming Delayed Price Updated: 2:06 PM EDT, Aug 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 229,867
Open 43.54
Bid (Size) 43.93 (300)
Ask (Size) 43.96 (300)
Prev. Close 43.50
Today's Range 42.65 - 44.00
52wk Range 14.47 - 45.42
Shares Outstanding 114,998,871
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Immunovant (IMVT) Q1 2027 Earnings Call Transcript ↗
CEO signals multiple pivotal data readouts ahead as cash runway supports IMVT-1402 development. 
Via The Motley Fool
Topics Earnings
News headline image
Immunovant Q1 Earnings Call Highlights ↗
Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple... 
Via MarketBeat
Topics Earnings

Performance

YTD
+69.6%
+69.6%
1 Month
+9.6%
+9.6%
3 Month
+29.9%
+29.9%
6 Month
+60.4%
+60.4%
1 Year
+195.1%
+195.1%

More News

Read More
News headline image
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
Immunovant Inc (NASDAQ:IMVT) Surges 26% Pre-Market on Strong IMVT-1402 Clinical Data Despite Wider Q4 Loss ↗
Via Chartmill
News headline image
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗
Via The Motley Fool
News headline image
These Analysts Increase Their Forecasts On Immunovant After Q4 Results ↗
Via Benzinga
Top movers in Wednesday's session ↗
Via Chartmill
News headline image
Immunovant Stock Surges Despite Disappointing Earnings Miss ↗
Via Benzinga
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
Immunovant Q4 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
Via The Motley Fool
News headline image
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Amgen’s Subcutaneous TEPEZZA Data Sets New Gold Standard for Thyroid Eye Disease Treatment
Via MarketMinute
News headline image
Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones
Via MarketMinute
Topics Intellectual Property
News headline image
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗
Via The Motley Fool
News headline image
Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough
Via Finterra
Topics Economy
News headline image
Air Taxi Stock Archer Aviation Draws $22.5 Million Institutional Buy. Here's What Investors Should Know ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish ↗
Via The Motley Fool
News headline image
Truth Social Stock Down 50% as One Investor Sells Off Nearly 800,000 Shares ↗
Via The Motley Fool
Topics Government
News headline image
Argenx (ARGX) 2026 Feature: The Anatomy of a Biotech Powerhouse Transitioning to Profitability
Via Finterra
Topics Earnings Economy Intellectual Property

Frequently Asked Questions

Is Immunovant, Inc. - Common Stock publicly traded?
Yes, Immunovant, Inc. - Common Stock is publicly traded.
What exchange does Immunovant, Inc. - Common Stock trade on?
Immunovant, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Immunovant, Inc. - Common Stock?
The ticker symbol for Immunovant, Inc. - Common Stock is IMVT on the Nasdaq Stock Market
What is the current price of Immunovant, Inc. - Common Stock?
The current price of Immunovant, Inc. - Common Stock is 43.94
When was Immunovant, Inc. - Common Stock last traded?
The last trade of Immunovant, Inc. - Common Stock was at 08/26/26 02:06 PM ET
What is the market capitalization of Immunovant, Inc. - Common Stock?
The market capitalization of Immunovant, Inc. - Common Stock is 5.05B
How many shares of Immunovant, Inc. - Common Stock are outstanding?
Immunovant, Inc. - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.